Odds of approval for LPCN’s Tlando come May 8th? H.
While Lipocine investors run for the hills following negative advisory committee meeting, Canaccord’s Dewey Steadman still sees a light at the end of the tunnel.
Lipocine Inc (NASDAQ:LPCN) failed to convince the Food and Drug Administration advisory committee that its phase 3 data testing TLANDO in hypogonadal male …
Canaccord’s Dewey Steadman says once LPCN’s Tlando gets the safety data it needs in hand to impress the FDA, a green light will flash.